SCHEMBL1339349

SCHEMBL1339349

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4cc[nH]n4)ccc3n(C)c21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ GAA P10253 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ CNR1 P21554 13/20 0.36
▸ CNR2 P34972 12/20 0.36
▸ HSD11B1 P28845 2/20 0.36
▸ F2RL3 Q96RI0 1/20 0.35
▸ GABRA1 P14867 2/20 0.34
▸ ADRA2C P18825 2/20 0.34
▸ SLC6A3 Q01959 2/20 0.34
▸ EGFR P00533 1/20 0.34
▸ ALOX5 P09917 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.34
▸ MAPK3 P27361 1/20 0.34
▸ OPRL1 P41146 1/20 0.34
▸ SLC18A2 Q05940 1/20 0.34
▸ MAPK14 Q16539 1/20 0.34
▸ TMEM97 Q5BJF2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4762650 0.90 CYP3A4 (0.34) KDM4EALDH1A1HPGDCNR1CNR2
SCHEMBL1338134 0.89 CNR1 (0.33) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL1339221 0.85 HSD11B1 (0.37) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL1337210 0.84 KDM4E (0.37) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL1338051 0.83 CNR1 (0.39) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL4912781 0.82 CNR1 (0.39) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL1339072 0.82 CNR1 (0.38) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL1338674 0.82 F2RL3 (0.37) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL1336985 0.81 MAPK14 (0.37) KDM4EGABRA1MAPK14
SCHEMBL3140269 0.81 RIPK2 (0.38) KDM4EALDH1A1HPGDGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed
EP-1940840-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2008-07-09 — — EP disclosed
WO-2007045758-A1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 KDM4E 1908/4885ALDH1A1 283/4885HPGD 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback